Alumis' stock dropped 56.58% after its Phase II lupus drug trial failed to meet main goals, causing a significant market reaction. However, positive results in a subgroup of lupus patients with a high interferon gene signature offer a potential path for future development. The company remains on track to submit a New Drug Application for its psoriasis treatment in Q4 2026, which supports some of its future value. An analyst lowered the price target from $35 to $27 amid these developments, with the stock trading at $9.47 per share at the time.
MillerKnoll reported a strong Q1 2027 earnings per share (EPS) of $0.53, surpassing analyst expectations by over 51%, helped by tariff refunds and improved cost management. However, its revenue fell 3.4% year-over-year to $923.40 million, missing est...
On September 22, 2026, Ethereum (ETH) traded around $2,735, just below a key resistance zone between $2,750 and $2,800 where it has repeatedly bounced. Despite a recent upward trend, ETH failed to sustain above $2,800, signaling uncertainty in short-...
FirstService Residential has published its 2026 BENCHMARK report detailing operating costs, budgets, and trends in large master-planned and lifestyle communities across North America. The report highlights key budget areas like insurance, utilities, ...
The ALPS Medical Breakthroughs ETF (SBIO) focuses on late-stage biotech companies that have at least one Phase II or III clinical program and sufficient cash reserves to reduce dilution risk before key events. This strategy aims to capture upside fro...
McDonald’s is piloting a program to sell advertising space on its digital menu boards, displayed after customers place orders in drive-thrus and restaurants. The company aims to offer relevant content without disrupting the McDonald’s experience. Thi...
